Enhanced Recovery After Surgery in Cytoreductive Surgery With HIPEC: Implementation and Outcomes From a High‐Volume Tertiary Centre in a Lower‐Middle Income Country
Journal of Surgical Oncology · 2026-06 · 133 (8) · 989-998
DOI: 10.1002/jso.70257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 08.04.2026. Verfasst von Babul Bansal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Dr. BRA-IRCH, AIIMS, Delhi, India. Hauptthemen laut MEDLINE: Cytoreduction Surgical Procedures, Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Neoplasms, Enhanced Recovery After Surgery. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significant morbidity. Enhanced Recovery After Surgery (ERAS) protocols may improve perioperative outcomes, but data from low‐ and middle‐income countries (LMICs) remain limited.
Methods
We conducted an ambispective study comparing patients undergoing CRS–HIPEC before (January 2015–June 2022; n = 294) and after (July 2022–June 2024; n = 70) ERAS implementation at a high‐volume tertiary cancer centre. ERAS compliance and perioperative outcomes, including length of stay (LOS), major morbidity (Clavien–Dindo III–IV), mortality, readmission, and reoperation, were analysed.
Results
Overall, ERAS compliance was 77.1%. Compliance was highest for preoperative and intraoperative components, while postoperative elements showed comparatively lower adherence. Median postoperative LOS decreased significantly from 8 to 5 days ( p = 0.02). Major morbidity declined from 20.1% to 12.9%, although this was not statistically significant. Ninety‐day mortality (4.6% vs 4.3%), readmission (15% vs 12.9%), and reoperation rates (13% vs 10%) were comparable between groups.
Conclusion
Implementation of an ERAS pathway for CRS–HIPEC in a high‐volume LMIC centre is feasible and safe, resulting in shorter hospital stay without increasing morbidity or mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Dr. BRA-IRCH, AIIMS, Delhi, India.
- Department of Onco-anesthesia and Palliative Medicine, Dr. BRA-IRCH, AIIMS, Delhi, India.
- Department of Surgical Oncology, National Cancer Institute AIIMS, Jhajjar, Haryana, India.
ORCID-Profile: Sandeep Bhoriwal
Zitieren
APA
Bansal, B., Ravi, V., Garg, R., Mishra, A., Bhoriwal, S., Mandal, A., Gupta, N., & Ray, M. D. (2026). Enhanced Recovery After Surgery in Cytoreductive Surgery With HIPEC: Implementation and Outcomes From a High‐Volume Tertiary Centre in a Lower‐Middle Income Country. Journal of Surgical Oncology, 133(8), 989-998. https://doi.org/10.1002/jso.70257
Vancouver
Bansal B, Ravi V, Garg R, Mishra A, Bhoriwal S, Mandal A, et al. Enhanced Recovery After Surgery in Cytoreductive Surgery With HIPEC: Implementation and Outcomes From a High‐Volume Tertiary Centre in a Lower‐Middle Income Country. Journal of Surgical Oncology. 2026;133(8):989-998. doi:10.1002/jso.70257
BibTeX
@article{Bansal2026,
author = {Bansal, Babul and Ravi, Venugopal and Garg, Rakesh and Mishra, Ashutosh and Bhoriwal, Sandeep and Mandal, Amitabha and Gupta, Nishkarsh and Ray, M D},
title = {Enhanced Recovery After Surgery in Cytoreductive Surgery With HIPEC: Implementation and Outcomes From a High‐Volume Tertiary Centre in a Lower‐Middle Income Country},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {133},
number = {8},
pages = {989--998},
doi = {10.1002/jso.70257}
}
EUVIMED